Drug Sponsors

Epic Sciences completes $13M Series B financing to advance cancer diagnostics

Wednesday, November 14, 2012 12:01 PM

Epic Sciences, a La Jolla, Calif.-based private biotech company that develops breakthrough cancer diagnostics, completed a $13 million Series B equity financing. This financing includes new investors Domain Associates, Roche Venture Fund and Pfizer Venture Investments, in addition to undisclosed individual investors.

More... »

Gilead to build new R&D facility

Wednesday, November 14, 2012 11:13 AM

Gilead Alberta ULC, a wholly-owned subsidiary of biopharmaceutical company Gilead Sciences, has entered an agreement with Eco Industrial Business Park to purchase and develop 10 acres of land at 1250 Hayter Road, in North East Edmonton, Canada. The transaction is anticipated to close in January 2013.

More... »

Pearl Therapeutics raises $65M Series D to start PT003 phase III trial

Wednesday, November 14, 2012 10:48 AM

Pearl Therapeutics, a Redwood City, Calif.-based privately held company developing combination therapies for the treatment of highly prevalent respiratory diseases, has raised a $65 million Series D financing from current investors.

More... »

EastBridge Investment Group to merge with Cellular Biomedicine Group

Wednesday, November 14, 2012 09:55 AM

EastBridge Investment Group has entered into an agreement to merge with Cellular Biomedicine Group (CBMG), a translational medicine company with serial preclinical and clinical research projects, as well as multiple planned clinical trials in the Greater China market. The combined company will be headquartered in Palo Alto, Calif.

More... »

Boehringer Ingelheim launches Hep C online resource

Tuesday, November 13, 2012 01:39 PM

Boehringer Ingelheim has launched HepCRedefined.com, an online portal to help improve the lives of those living with the hepatitis C virus (HCV) through education, information and understanding. The portal aims to redefine the HCV journey by providing downloadable and shareable resources to healthcare providers, advocates, caregivers and patients.

More... »

GlaxoSmithKline honors healthcare nonprofits with $40,000 IMPACT Awards

Friday, November 9, 2012 02:02 PM

GlaxoSmithKline has announced five recipients of its annual GlaxoSmithKline IMPACT Awards. In total, the North Carolina and Philadelphia-area healthcare nonprofit organizations will receive $200,000 in grant funding ($40,000 each) for providing access to healthcare for the underserved in their communities.

More... »

Boston Scientific to acquire Vessix Vascular

Friday, November 9, 2012 12:28 PM

Boston Scientific, a medical device company based in Natick, Mass., is extending its reach into the strategically critical renal denervation market by signing a definitive agreement to acquire Vessix Vascular, a Laguna Hills, Calif.-based held company developing novel RF balloon catheter and bipolar RF generator technology. 

More... »

Sun Pharma to acquire DUSA Pharmaceuticals

Friday, November 9, 2012 12:06 PM

Sun Pharmaceutical, an international, specialty pharmaceutical company based in India, has agreed to acquire DUSA Pharmaceuticals, a Wilmington, Mass.-based dermatology company focused on photodynamic therapy.

More... »

Bausch + Lomb to acquire Technolas Perfect Vision

Friday, November 9, 2012 11:46 AM

Bausch + Lomb, a global eye health company, has exercised its option to purchase all outstanding and unowned shares of Technolas Perfect Vision (TPV), a ophthalmology laser company based in Germany.

More... »

CEO of Sanofi designated as new president elect of EFPIA

Wednesday, November 7, 2012 01:55 PM

The European Federation of Pharmaceutical Industries and Associations (EFPIA), which represents the pharmaceutical industry operating in Europe, has designated Christopher A. Viehbacher, CEO of Sanofi, as the new president elect of EFPIA. He will take up the position as of June 2013 for a two year term.

More... »